Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Moschini

Showing results (21-30 of 560) with videos related to

Pageof 56
Sort By:
Translational Andrology and Urology|April 13, 2019
The present and future of non-muscle invasive bladder cancerMarco Moschini, Florian Roghmann, Evanguelos Xylinas
Cell Reports. Medicine|December 18, 2024
Reflections on the AMBASSADOR trial: The role of adjuvant pembrolizumab in muscle-invasive urothelial carcinomaPietro Scilipoti, Marco Moschini, Alberto Briganti
The Journal of Urology|May 13, 2021
Editorial CommentChiara Lonati, Claudio Simeone, Marco Moschini
European Urology Open Science|August 2, 2021
Neoadjuvant Immunotherapy: The Next Gold Standard Before Radical Surgery for Urothelial CancerDaniele Raggi, Marco Moschini, Andrea Necchi
European Urology|April 17, 2019
Re: Impact of Adjuvant Chemotherapy in Patients with Adverse Features and Variant Histology at Radical Cystectomy for Muscle-invasive Carcinoma of the Bladder: Does Histologic Subtype Matter?Marco Moschini, Idir Ouzaid, Evanguelos Xylinas, et al.
Translational Andrology and Urology|April 13, 2019
The need to improve TURB: a diagnostic and therapeutic fundamental first step in the disease's managementMarco Moschini, Florian Roghmann, Evanguelos Xylinas
European Urology Oncology|April 8, 2023
Re: Wei Shan Tan, Gary Steinberg, J. Alfred Witjes, et al. Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. Eur Urol Oncol 2022;5:505-16Francesco Montorsi, Marco Moschini, Alberto Briganti
BJU International|August 18, 2020
CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancerFrancesco Montorsi, Marco Moschini, Andrea Necchi
European Urology|February 18, 2024
Re: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trialMarco Moschini, Andrea Necchi, Francesco Montorsi
The Journal of Urology|April 10, 2023
Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. LetterMarco Moschini, Andrea Necchi, Alberto Briganti, et al.
Pageof 56

Showing results (21-30 of 560) with videos related to

Sort By:
Pageof 56
Translational Andrology and Urology|April 13, 2019
The present and future of non-muscle invasive bladder cancerMarco Moschini, Florian Roghmann, Evanguelos Xylinas
Cell Reports. Medicine|December 18, 2024
Reflections on the AMBASSADOR trial: The role of adjuvant pembrolizumab in muscle-invasive urothelial carcinomaPietro Scilipoti, Marco Moschini, Alberto Briganti
The Journal of Urology|May 13, 2021
Editorial CommentChiara Lonati, Claudio Simeone, Marco Moschini
European Urology Open Science|August 2, 2021
Neoadjuvant Immunotherapy: The Next Gold Standard Before Radical Surgery for Urothelial CancerDaniele Raggi, Marco Moschini, Andrea Necchi
European Urology|April 17, 2019
Re: Impact of Adjuvant Chemotherapy in Patients with Adverse Features and Variant Histology at Radical Cystectomy for Muscle-invasive Carcinoma of the Bladder: Does Histologic Subtype Matter?Marco Moschini, Idir Ouzaid, Evanguelos Xylinas, et al.
Translational Andrology and Urology|April 13, 2019
The need to improve TURB: a diagnostic and therapeutic fundamental first step in the disease's managementMarco Moschini, Florian Roghmann, Evanguelos Xylinas
European Urology Oncology|April 8, 2023
Re: Wei Shan Tan, Gary Steinberg, J. Alfred Witjes, et al. Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. Eur Urol Oncol 2022;5:505-16Francesco Montorsi, Marco Moschini, Alberto Briganti
BJU International|August 18, 2020
CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancerFrancesco Montorsi, Marco Moschini, Andrea Necchi
European Urology|February 18, 2024
Re: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trialMarco Moschini, Andrea Necchi, Francesco Montorsi
The Journal of Urology|April 10, 2023
Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. LetterMarco Moschini, Andrea Necchi, Alberto Briganti, et al.
Pageof 56